BR112015003957A2 - alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria - Google Patents
alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndriaInfo
- Publication number
- BR112015003957A2 BR112015003957A2 BR112015003957A BR112015003957A BR112015003957A2 BR 112015003957 A2 BR112015003957 A2 BR 112015003957A2 BR 112015003957 A BR112015003957 A BR 112015003957A BR 112015003957 A BR112015003957 A BR 112015003957A BR 112015003957 A2 BR112015003957 A2 BR 112015003957A2
- Authority
- BR
- Brazil
- Prior art keywords
- microglobulin
- alpha
- treatment
- mitochondrial
- related diseases
- Prior art date
Links
- 102000003966 Alpha-1-microglobulin Human genes 0.000 title abstract 3
- 101800001761 Alpha-1-microglobulin Proteins 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000002438 mitochondrial effect Effects 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201270538 | 2012-09-05 | ||
| DKPA201270557 | 2012-09-12 | ||
| PCT/EP2013/068270 WO2014037390A1 (en) | 2012-09-05 | 2013-09-04 | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015003957A2 true BR112015003957A2 (pt) | 2017-08-08 |
Family
ID=49162118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015003957A BR112015003957A2 (pt) | 2012-09-05 | 2013-09-04 | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10226507B2 (https=) |
| EP (1) | EP2900254B1 (https=) |
| JP (2) | JP2015533790A (https=) |
| KR (1) | KR20150047510A (https=) |
| CN (1) | CN104661673A (https=) |
| AU (1) | AU2013311714C1 (https=) |
| BR (1) | BR112015003957A2 (https=) |
| CA (1) | CA2881321A1 (https=) |
| DK (1) | DK2900254T3 (https=) |
| EA (1) | EA028963B1 (https=) |
| ES (1) | ES2599034T3 (https=) |
| HR (1) | HRP20161364T1 (https=) |
| HU (1) | HUE030559T2 (https=) |
| IN (1) | IN2015DN00515A (https=) |
| MX (1) | MX357656B (https=) |
| NZ (1) | NZ629621A (https=) |
| PL (1) | PL2900254T3 (https=) |
| PT (1) | PT2900254T (https=) |
| SG (1) | SG11201500669SA (https=) |
| WO (1) | WO2014037390A1 (https=) |
| ZA (1) | ZA201500547B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016204360A (ja) * | 2015-02-25 | 2016-12-08 | エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ | 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン |
| US20190054142A1 (en) * | 2016-02-25 | 2019-02-21 | A1M Pharma Ab | Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media |
| US10981963B2 (en) * | 2016-03-18 | 2021-04-20 | Guard Therapeutics International AB | Alpha-1-microglobulin derived proteins and their use |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| CN109867717A (zh) * | 2019-04-01 | 2019-06-11 | 山西瑞亚力生物技术有限公司 | 一种血浆中α1微球蛋白的提取方法 |
| CN110452980B (zh) * | 2019-09-23 | 2023-07-28 | 武汉儿童医院 | 一种线粒体脑肌病诊断试剂盒及应用 |
| WO2021062007A1 (en) * | 2019-09-25 | 2021-04-01 | Cytegen Corp. | Treatment of mitochondrial deficits and age-related diseases using blood products |
| CN115575646B (zh) * | 2022-11-21 | 2023-04-28 | 四川大学华西医院 | 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2547124A1 (en) * | 2003-11-26 | 2005-06-09 | Sanofi-Aventis Deutschland Gmbh | Tubular proteinuria as an indicator for elevated cardiovascular risk |
| EA022609B1 (ru) * | 2007-02-12 | 2016-02-29 | А1М Фарма Аб | Применение свободного фетального гемоглобина в качестве маркера преэклампсии |
| ES2560097T3 (es) * | 2008-02-04 | 2016-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Procedimientos y composiciones de tratamiento de trastornos mitocondriales |
| CA2730531A1 (en) * | 2008-07-18 | 2010-01-21 | A1M Pharma Ab | Medical use of the radical scavenger and antioxidant alpha-1-microglobulin |
-
2013
- 2013-09-04 US US14/423,260 patent/US10226507B2/en not_active Expired - Fee Related
- 2013-09-04 SG SG11201500669SA patent/SG11201500669SA/en unknown
- 2013-09-04 PL PL13759995T patent/PL2900254T3/pl unknown
- 2013-09-04 JP JP2015530375A patent/JP2015533790A/ja active Pending
- 2013-09-04 HR HRP20161364TT patent/HRP20161364T1/hr unknown
- 2013-09-04 PT PT137599957T patent/PT2900254T/pt unknown
- 2013-09-04 AU AU2013311714A patent/AU2013311714C1/en not_active Ceased
- 2013-09-04 IN IN515DEN2015 patent/IN2015DN00515A/en unknown
- 2013-09-04 CN CN201380043567.0A patent/CN104661673A/zh active Pending
- 2013-09-04 EP EP13759995.7A patent/EP2900254B1/en not_active Not-in-force
- 2013-09-04 KR KR1020157005748A patent/KR20150047510A/ko not_active Ceased
- 2013-09-04 ES ES13759995.7T patent/ES2599034T3/es active Active
- 2013-09-04 EA EA201590503A patent/EA028963B1/ru not_active IP Right Cessation
- 2013-09-04 CA CA2881321A patent/CA2881321A1/en not_active Abandoned
- 2013-09-04 DK DK13759995.7T patent/DK2900254T3/en active
- 2013-09-04 NZ NZ629621A patent/NZ629621A/en not_active IP Right Cessation
- 2013-09-04 HU HUE13759995A patent/HUE030559T2/en unknown
- 2013-09-04 WO PCT/EP2013/068270 patent/WO2014037390A1/en not_active Ceased
- 2013-09-04 MX MX2015002604A patent/MX357656B/es active IP Right Grant
- 2013-09-04 BR BR112015003957A patent/BR112015003957A2/pt not_active Application Discontinuation
-
2015
- 2015-01-23 ZA ZA2015/00547A patent/ZA201500547B/en unknown
-
2018
- 2018-08-24 JP JP2018157394A patent/JP2018203756A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA028963B1 (ru) | 2018-01-31 |
| MX357656B (es) | 2018-07-18 |
| KR20150047510A (ko) | 2015-05-04 |
| AU2013311714A1 (en) | 2015-03-12 |
| PL2900254T3 (pl) | 2017-02-28 |
| JP2015533790A (ja) | 2015-11-26 |
| US10226507B2 (en) | 2019-03-12 |
| PT2900254T (pt) | 2016-10-18 |
| MX2015002604A (es) | 2015-06-10 |
| AU2013311714C1 (en) | 2018-01-25 |
| CN104661673A (zh) | 2015-05-27 |
| HRP20161364T1 (hr) | 2016-12-16 |
| NZ629621A (en) | 2015-09-25 |
| WO2014037390A1 (en) | 2014-03-13 |
| US20150258171A1 (en) | 2015-09-17 |
| JP2018203756A (ja) | 2018-12-27 |
| IN2015DN00515A (https=) | 2015-06-26 |
| EP2900254B1 (en) | 2016-08-03 |
| CA2881321A1 (en) | 2014-03-13 |
| DK2900254T3 (en) | 2016-08-29 |
| HK1210585A1 (en) | 2016-04-29 |
| EP2900254A1 (en) | 2015-08-05 |
| AU2013311714B2 (en) | 2017-10-12 |
| ZA201500547B (en) | 2017-09-27 |
| ES2599034T3 (es) | 2017-01-31 |
| SG11201500669SA (en) | 2015-02-27 |
| HUE030559T2 (en) | 2017-05-29 |
| EA201590503A1 (ru) | 2015-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY33863A (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| IL269511A (en) | New therapeutic approaches for treating parkinson's disease | |
| BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria | |
| ECSP14013224A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| BR112015021521A2 (pt) | anticorpos anti-crth2 e métodos para seu uso | |
| UY33627A (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CR20170060A (es) | Anticuerpos anti tigit | |
| MX391043B (es) | Formulaciones de anticuerpo y metodos. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| BR112015000329A2 (pt) | formulações de diclofenac | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| HUE054783T2 (hu) | Pridopidin Huntington-kór kezelésében | |
| BR112014030406A2 (pt) | combinação de canabidiol fitocanabinoide com hipotermia terapêutica | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| DOP2014000255A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| BR112013022052A2 (pt) | ligantes antagonísticos de dr3 | |
| BR112015008824A2 (pt) | linhagens melhoradas de microalgas e processo das mesmas | |
| BR112014005935A2 (pt) | derivados de anilina, sua preparação e sua aplicação terapêutica | |
| EP2695154A4 (en) | PROVIDING A COMPUTER-BASED LANGUAGE THERAPY | |
| ES2627541T8 (es) | Métodos para tratar la enfermedad de Parkinson | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| TR201905218T4 (tr) | Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler. | |
| BR112015009088A2 (pt) | formulações de levodopa para alívio rápido da doença de parkinson. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B25G | Requested change of headquarter approved |
Owner name: A1M PHARMA AB (SE) |
|
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |